IL149701A0 - Use of anti-ctla-4 antibodies - Google Patents

Use of anti-ctla-4 antibodies

Info

Publication number
IL149701A0
IL149701A0 IL14970102A IL14970102A IL149701A0 IL 149701 A0 IL149701 A0 IL 149701A0 IL 14970102 A IL14970102 A IL 14970102A IL 14970102 A IL14970102 A IL 14970102A IL 149701 A0 IL149701 A0 IL 149701A0
Authority
IL
Israel
Prior art keywords
ctla
antibodies
Prior art date
Application number
IL14970102A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL149701A0 publication Critical patent/IL149701A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14970102A 2001-05-23 2002-05-16 Use of anti-ctla-4 antibodies IL149701A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29304201P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
IL149701A0 true IL149701A0 (en) 2002-11-10

Family

ID=23127385

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14970102A IL149701A0 (en) 2001-05-23 2002-05-16 Use of anti-ctla-4 antibodies

Country Status (14)

Country Link
US (1) US20030086930A1 (en:Method)
EP (1) EP1262193A1 (en:Method)
JP (1) JP2002371013A (en:Method)
KR (1) KR100531707B1 (en:Method)
CN (1) CN1404876A (en:Method)
AU (1) AU4242102A (en:Method)
CA (1) CA2382443A1 (en:Method)
CZ (1) CZ20021760A3 (en:Method)
HU (1) HUP0201737A2 (en:Method)
IL (1) IL149701A0 (en:Method)
MY (1) MY136095A (en:Method)
PL (1) PL354112A1 (en:Method)
SK (1) SK7242002A3 (en:Method)
ZA (1) ZA200204020B (en:Method)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
CN1652820A (zh) * 2002-04-12 2005-08-10 梅达雷克斯公司 使用ctla－4抗体的治疗方法
NZ605429A (en) * 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
BRPI0411852A (pt) 2003-06-27 2006-05-23 Abgenix Inc anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos
CN1826138B (zh) 2003-07-22 2012-05-23 舍林股份公司 Rg1抗体及其用途
JP2007528721A (ja) * 2003-08-14 2007-10-18 ダイアックス コーポレイション エンドセリアーゼ−２リガンド
EP1515505A1 (en) * 2003-09-12 2005-03-16 Siemens Aktiengesellschaft Reachability maintainance of a moving network based on temporary name identifiers
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
JP2007530526A (ja) * 2004-03-26 2007-11-01 ファイザー・プロダクツ・インク 抗ｃｔｌａ−４抗体の使用
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP1819735A1 (en) * 2004-11-04 2007-08-22 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
AU2006220828A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-MAdCAM antibody compositions
BRPI0607579A2 (pt) * 2005-03-23 2009-09-15 Pfizer Prod Inc uso de anticorpo anti-ctla4 e indolinona para a preparação de medicamentos para o tratamento de cáncer
KR20070108259A (ko) * 2005-03-23 2007-11-08 화이자 프로덕츠 인크. Ｃｔｌａ-4 항체와 호르몬 요법에 의한 전립선암의 치료법
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SG10201702670VA (en) 2005-06-08 2017-06-29 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
SG163583A1 (en) * 2005-07-07 2010-08-30 Coley Pharm Group Inc Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
AU2006321593B2 (en) 2005-12-07 2012-10-04 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
JP2010534719A (ja) * 2007-07-27 2010-11-11 ファイザー・リミテッド 沈殿化による抗体精製方法
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
RU2373836C2 (ru) * 2007-12-18 2009-11-27 Федеральное государственное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова Федерального агентства по высокотехнологичной медицинской помощи" Способ оптимизации лечебной тактики при лимфоме ходжкина у детей и подростков
KR20100100949A (ko) 2008-01-08 2010-09-15 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
SMT201700293T1 (it) * 2009-07-20 2017-07-18 Bristol Myers Squibb Co Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative
RU2421217C2 (ru) * 2009-09-03 2011-06-20 Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
CA3019531A1 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2012167173A1 (en) 2011-06-02 2012-12-06 The University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
CN104334577A (zh) 2012-03-13 2015-02-04 霍夫曼-拉罗奇有限公司 治疗卵巢癌的联合疗法
EP3563865A3 (en) 2012-05-04 2019-12-04 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens
CN111330016B (zh) * 2012-08-23 2025-03-25 艾更斯司股份有限公司 结合158p1d7蛋白的抗体药物偶联物(adc)
PT2925350T (pt) * 2012-12-03 2019-03-25 Bristol Myers Squibb Co Melhoria da atividade anticancerosa de proteínas de fusão de fc imunomoduladoras
CA2919725C (en) 2013-08-08 2023-04-18 Cytune Pharma An il-15 and il-15r.aplha. sushi domain based modulokines
ES2760249T3 (es) 2013-08-08 2020-05-13 Cytune Pharma Composición farmacéutica combinada
CN105636986B (zh) * 2013-10-18 2020-05-12 瑞泽恩制药公司 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
US12427173B2 (en) * 2014-03-31 2025-09-30 Biomed Valley Discoveries, Inc. Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
US10443061B2 (en) * 2014-05-01 2019-10-15 Anaeropharma Science, Inc. Heterologous polypeptide expression cassette
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
EP3204516B1 (en) 2014-10-06 2023-04-26 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
NZ746680A (en) 2014-10-14 2020-07-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US10682365B2 (en) 2014-12-31 2020-06-16 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
JP6917902B2 (ja) * 2015-02-13 2021-08-11 ソレント・セラピューティクス・インコーポレイテッド Ｃｔｌａ４に結合する抗体医薬
CA3020885A1 (en) 2015-05-05 2016-11-10 Mohammad Tariq MALIK Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
LT3303394T (lt) 2015-05-29 2020-10-12 Agenus Inc. Anti-ctla-4 antikūnai ir jų naudojimo būdai
CN108348601B (zh) * 2015-07-22 2022-05-17 索伦托药业有限公司 与lag3结合的抗体治疗剂
WO2017031157A1 (en) * 2015-08-18 2017-02-23 Mateon Therapeutics, Inc. Use of vdas to enhance immunomodulating therapies against tumors
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
EP3436066A1 (en) 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
EA039322B1 (ru) * 2016-04-15 2022-01-13 Эйдженус Инк. Антитела против ctla-4 и способы их применения
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018037595A1 (ja) * 2016-08-26 2018-03-01 哲治 奥野 微小血管血流低減剤およびその利用
MD3551660T2 (ro) * 2016-12-07 2024-03-31 Agenus Inc Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
US12129299B2 (en) 2018-02-02 2024-10-29 OncoC4, Inc. Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. ANTI-TUMOR IMMUNOTHERAPY COMPOSITIONS AND METHODS
CN112218892B (zh) * 2018-03-19 2023-04-25 上海药明生物技术有限公司 新型抗ctla-4抗体多肽
WO2019197965A1 (en) 2018-04-09 2019-10-17 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN110092826B (zh) * 2019-02-28 2022-04-15 天津大学 CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
CN115803343A (zh) * 2020-05-26 2023-03-14 百奥泰生物制药股份有限公司 多特异性抗体及其应用
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
EP4343004A3 (en) 2020-10-19 2024-09-11 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
EP4326321A1 (en) 2021-04-20 2024-02-28 Institut Curie Compositions and methods for use in immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
SI2112166T1 (sl) * 1998-12-23 2019-05-31 Pfizer Inc. Človeška monoklonska protitelesa proti CTLA-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP4093757B2 (ja) * 1999-08-24 2008-06-04 メダレックス， インコーポレイテッド ヒトｃｔｌａ−４抗体およびその使用
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules

Also Published As

Publication number Publication date
CN1404876A (zh) 2003-03-26
ZA200204020B (en) 2003-11-21
KR20020090873A (ko) 2002-12-05
CZ20021760A3 (cs) 2003-05-14
JP2002371013A (ja) 2002-12-26
PL354112A1 (en) 2002-12-02
SK7242002A3 (en) 2003-07-01
EP1262193A1 (en) 2002-12-04
KR100531707B1 (ko) 2005-11-30
MY136095A (en) 2008-08-29
AU4242102A (en) 2002-11-28
CA2382443A1 (en) 2002-11-23
HUP0201737A2 (hu) 2003-02-28
HU0201737D0 (en:Method) 2002-07-29
US20030086930A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
IL149701A0 (en) Use of anti-ctla-4 antibodies
IL212419A0 (en) Methods of administering anti-tnf antibodies
EP1432444A4 (en) ANTI-BETA ANTIBODIES
HUP0402164A3 (en) Polycistronic expression of antibodies
HU230006B1 (en) Antagonistic anti-htnfsf13b human antibodies
ZA200305825B (en) Modified antibodies and methods of use
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
IL175935A0 (en) Solid forms of anti-egfr antibodies
EP1539233A4 (en) SUPER HUMANIZED ANTIBODIES
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2002365649A8 (en) Anti-dota antibody
GB0126378D0 (en) Antigen
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
IL158950A0 (en) Use of polyclonal immunoglobulins
AU2002242447A1 (en) Use of polyclonal immunoglobulins
EP1446416A4 (en) TUMOR-SPECIFIC MONOCLONAL ANTIBODIES
ZA200508071B (en) Polycistronic expression of antibodies
GB0119553D0 (en) Antibodies
GB0121727D0 (en) Monoclonal antibodies
GB0118696D0 (en) Novel antibodies
GB0119004D0 (en) Antibody
GB0120494D0 (en) Novel antibody
AU2002211364A1 (en) Human anti-cd40 antibodies
GB0126522D0 (en) Antigen